Albireo Pharma

Financial Investors

Albireo is a unique and exciting investment opportunity. The high quality programmes led by a management team with extensive experience in scientific and clinical development in the GI field, as well as extensive links to industry and academia, enabled Albireo to raise $40m in a Series A financing round from leading healthcare investors.

Phase4 Ventures is a leading venture capital firm based in London that invests in development stage life science companies in the US and Europe. Founded in 1999, the team has made more than 30 investments in mid-to-late stage life science companies. The team is complemented by an extensive group of advisors with operating experience at a senior level in pharmaceutical and biotechnology companies. Phase4 investments have included many of the companies that provided successful European and US venture exits in recent years including Intercell, Pharmion, Targacept and most recently Proteolix.
Phase4 Ventures was spun-out from Nomura in December 2010 following a buy out of the management company by the team and a secondary purchase of a fund by Harbourvest Partners. Phase4 currently manages funds for both Nomura and Harbourvest.

Phase4 Ventures

 

TPG Biotech was founded in 2001 and has over $700M of capital under management anda team of experts in healthcare to catalyze the creation of newbusinesses. We invest in five main areas - drug discovery anddevelopment, personalized diagnostics, pharmaceutical outsourcing businesses,industrial biotechnology and medical devices. We invest across the full spectrumof company stage, from making seed investments and starting companies toinvesting in public companies. We aim to invest $25-30MM in each company overthe lifetime of our investment.

 TPG Biotech

TVM Capital funds have made investments in more than 235 technology and life science companies. Over the life of the firm, TVM Capital has developed specialized, focused teams and dedicated funds to serve high-growth target markets. The TVM Capital investment strategy is to create global businesses that enjoy worldwide access to science, technology, management talent and capital, and to develop them into significant players in their markets. More than 50 TVM Capital backed companies have gone public on European or US stock exchanges. Today, TVM Capital is actively invested in 70 companies, including three growth capital investments in specialty pharmaceutical companies from its current fund.

TVM Capital 

Scottish Widows Investment Partnership (SWIP) is one of Europe's largest asset management companies and part of the Lloyds TSB Group. SWIP managed funds worth £97.6bn (as at 31 December 2007), which are invested in all major asset classes, including domestic and overseas equities, property, bonds and cash. Under its own name and in partnership with overseas-based organisations, SWIP has a physical presence that stretches around the world. SWIP's forward looking approach combines the strength of its investment team with some of the most advanced technology used in asset management today.